Elicio Therapeutics Inc
NASDAQ:ELTX
Balance Sheet
Balance Sheet Decomposition
Elicio Therapeutics Inc
Elicio Therapeutics Inc
Balance Sheet
Elicio Therapeutics Inc
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
26
|
6
|
35
|
89
|
50
|
13
|
18
|
|
| Cash Equivalents |
26
|
6
|
35
|
89
|
50
|
13
|
18
|
|
| Total Receivables |
0
|
0
|
5
|
1
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
3
|
2
|
1
|
3
|
3
|
|
| Total Current Assets |
26
|
6
|
42
|
91
|
51
|
16
|
21
|
|
| PP&E Net |
0
|
5
|
4
|
4
|
0
|
7
|
6
|
|
| PP&E Gross |
0
|
5
|
4
|
4
|
0
|
7
|
6
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
1
|
1
|
2
|
|
| Long-Term Investments |
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
4
|
1
|
|
| Total Assets |
27
N/A
|
12
-55%
|
47
+298%
|
97
+104%
|
53
-45%
|
27
-49%
|
28
+4%
|
|
| Liabilities | ||||||||
| Accounts Payable |
1
|
11
|
6
|
5
|
3
|
4
|
1
|
|
| Accrued Liabilities |
3
|
4
|
7
|
4
|
2
|
5
|
9
|
|
| Short-Term Debt |
0
|
6
|
51
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
4
|
6
|
43
|
2
|
2
|
1
|
1
|
|
| Total Current Liabilities |
7
|
27
|
107
|
11
|
6
|
10
|
12
|
|
| Long-Term Debt |
0
|
0
|
1
|
0
|
0
|
0
|
20
|
|
| Other Liabilities |
0
|
4
|
30
|
3
|
2
|
6
|
8
|
|
| Total Liabilities |
8
N/A
|
30
+295%
|
138
+352%
|
15
-89%
|
9
-40%
|
16
+75%
|
39
+150%
|
|
| Equity | ||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
40
|
80
|
161
|
215
|
254
|
142
|
194
|
|
| Additional Paid In Capital |
60
|
64
|
72
|
296
|
297
|
154
|
183
|
|
| Treasury Stock |
2
|
2
|
2
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
19
N/A
|
19
N/A
|
90
-387%
|
82
N/A
|
44
-46%
|
11
-74%
|
11
N/A
|
|
| Total Liabilities & Equity |
27
N/A
|
12
-55%
|
47
+298%
|
97
+104%
|
53
-45%
|
27
-49%
|
28
+4%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
1
|
1
|
2
|
3
|
3
|
10
|
11
|
|